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Introduction: The transcription factor GATA3 is involved in mammary gland development and is crucial for the
maintenance of the differentiated status of luminal epithelial cells. The role of GATA3 in breast cancer as a tumor
suppressor has been established, although insights into the mechanism of GATA3 expression loss are still required.
Methods: Chromatin immunoprecipitation assays were conducted to study progestin modulation of recruitment of
transcription factors to GATA3 promoter. We performed western blot and reverse RT-qPCR experiments to explore
progestin regulation of GATA3 protein and mRNA expression respectively. Confocal microscopy and in vitro
phosphorylation studies were conducted to examine progestin capacity to induce GATA3 serine phosphorylation in
its 308 residue. GATA3 participation in progestin-induced breast cancer growth was addressed in in vitro proliferation
and in vivo tumor growth experiments.
Results: In this study, we demonstrate that progestin-activated progesterone receptor (PR) reduces GATA3 expression
through regulation at the transcriptional and post-translational levels in breast cancer cells. In the former mechanism,
the histone methyltransferase enhancer of zeste homolog 2 is co-recruited with activated PR to a putative progesterone
response element in the GATA3 proximal promoter, increasing H3K27me3 levels and inducing chromatin compaction,
resulting in decreased GATA3 mRNA levels. This transcriptional regulation is coupled with increased GATA3 protein
turnover through progestin-induced GATA3 phosphorylation at serine 308 followed by 26S proteasome-mediated
degradation. Both molecular mechanisms converge to accomplish decreased GATA3 expression levels in breast cancer
cells upon PR activation. In addition, we demonstrated that decreased GATA3 levels are required for progestin-induced
upregulation of cyclin A2, which mediates the G1 to S phase transition of the cell cycle and was reported to be associated
with poor prognosis in breast cancer. Finally, we showed that downregulation of GATA3 is required for progestin
stimulation of both in vitro cell proliferation and in vivo tumor growth.
Conclusions: In the present study, we reveal that progestin-induced PR activation leads to loss of GATA3 expression
in breast cancer cells through transcriptional and post-translational regulation. Importantly, we demonstrate that GATA3
downregulation is required for progestin-induced upregulation of cyclin A2 and for progestin-induced in vitro and
in vivo breast cancer cell growth.* Correspondence: patriciaelizalde@ibyme.conicet.gov.ar; cproietti@ibyme.
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Progesterone is an ovarian steroid hormone essential for
breast development and implicated in breast cancer pro-
gression. Progesterone receptors (PR) exist primarily as
two coexpressed isoforms, PR-A and PR-B [1] encoded
in the same gene downstream of distinct promoters [2].
Ligand binding triggers a network of signaling events
which targets PR and the protein components of chro-
matin resulting in chromatin remodeling for access of
transcription factors to DNA [3]. Nuclear PR, together
with coregulators, activates or represses transcription of PR
target genes, either directly through DNA binding to pro-
gesterone response elements (PRE) or indirectly through
tethering interactions with other transcription factors [4-7].
Recent genome-wide studies showed that 63% of the PR
binding sites associated with transcriptional gene regulation
contain PREs within PR binding sites [8]. However, the lack
of strong PREs in other PR binding sites highlights the
relevance of additional regulatory mechanisms such as
tethering, pioneer transcription factor binding and PR
cofactor recruitment, which may account for cell-specific
PR cistromes [8].
On the other hand, the GATA family of transcription
factors is involved in cell fate determination [9]. It has
been demonstrated that GATA3 is a critical regulator in
both mouse and human development, since constitutive
null mutations of GATA3 result in embryonic lethality
[10]. Recent evidence identified GATA3 as the most
highly expressed transcription factor in the terminal end
buds of the mammary gland during development [11].
In addition, GATA3 expression is necessary for specifi-
cation and maintenance of both ductal and alveolar lu-
minal cell fate [11,12]. The requirement of GATA3 for
the development of the mammary gland and for the
maintenance of the luminal cell fate suggested potential
implications for GATA3 in the breast cancer scenario.
Using the mouse mammary tumor virus LTR-driven poly-
oma middle T antigen (MMTV-PyMT) mouse model of
tumor progression, Kouros-Mehr et al. demonstrated that
GATA3 is downregulated in carcinomas compared to ad-
enomas, and that GATA3 is the only member of the
GATA family of transcription factors which is differen-
tially expressed between these two subsets [13]. Import-
antly, it was demonstrated that the loss of GATA3
expression marks the loss of tumor differentiation and
the onset of tumor dissemination [13]. Remarkably, re-
constitution of GATA3 expression by retroviral transduc-
tion of MMTV-PyMT mice tumor outgrowths proved to
be sufficient to suppress tumor dissemination. In addition,
restoration of GATA3 induced differentiation of mam-
mary ductal adenocarcinomas [13]. As demonstrated
by a transgenic mouse model overexpressing GATA3,
increased expression of GATA3 delays tumor growth,
reduces tumor-initiating capacity and increases tumordifferentiation [14]. Collectively, these findings high-
light the capability of GATA3 to induce functional dif-
ferentiation of mammary ductal adenocarcinomas and
reduction of the tumor initiating capacity in transplanted
tumor cells. However, silencing of the GATA3 locus is not
sufficient to promote malignant progression, since prema-
ture loss of GATA3 expression in well-differentiated aden-
omas promotes widespread detachment of cells from the
basement membrane followed by apoptosis [13]. In
breast cancer patients, GATA3 expression displays a
steady decrease with increasing tumor grade [15], and
several independent studies demonstrated that GATA3
expression holds independent prognostic value, with in-
creased GATA3 expression correlating with good progno-
sis [15-19]. A recent study identified GATA3 as one of the
only three genes carrying somatic mutations with more
than 10% incidence across breast cancer subtypes defined
by the mRNA expression profile [20]. Taken together,
these studies highlight the role of GATA3 as a tumor
suppressor.
A functional link between GATA3 expression and the
histone methyltransferase enhancer of zeste homolog 2
(EZH2) has been suggested, since EZH2 knockdown in
basal-like breast cancer cells promotes the increase of
GATA3 expression levels [21]. EZH2 is the catalytic sub-
unit of the Polycomb Repressor Complex 2 (PRC2), and
catalyzes the tri-methylation of lysine 27 of histone H3
(H3K27me3), a histone mark associated with chromatin
compaction and transcriptional repression [22,23]. Notably,
Polycomb group (PcG) target genes are mainly involved in
embryonic development and cell differentiation [24].
During pregnancy, EZH2 expression levels, phosphor-
ylation of EZH2 at threonine 487 (pT487-EZH2) and
total H3K27me3 are increased in the mammary gland,
correlating with increased progesterone levels and PR ex-
pression. Moreover, PR knockdown results in decreased
pT487-EZH2 in the human breast cancer cell line T47D
[25]. Overexpression of EZH2 has been detected in breast
cancer, with increased EZH2 levels correlating with higher
proliferation rates, neoplastic transformation and more
aggressive cancer subtypes [26,27].
On the other hand, cyclin A has a role in mediating
the transition of G1 to S and G2 to M phase of the cell
cycle, since it is required for the onset of DNA replica-
tion and mitosis [28,29]. While expression of cyclin A1
is limited to meiosis of germinal cells and early embryos,
cyclin A2 is expressed in proliferating somatic cells. Po-
tential implications of cyclin A2 in breast cancer have
been suggested, since transgenic mice overexpressing
cyclin A2 generate aberrant nuclear abnormalities suggestive
of preneoplasic alterations [30]. In addition, cyclin A2 ex-
pression levels have been shown to have independent prog-
nostic value in breast cancer patients, with increased
expression correlating with poor outcome [31]. Accordingly,
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MDA-MB-231 breast cancer cells engineered to overexpress
GATA3 [32].
In the present work, we demonstrated that progestin-
induced PR activation promotes the loss of GATA3 expres-
sion in breast cancer cells through transcriptional and post-
translational regulation. Finally, we have also shown that
GATA3 downregulation is required for progestin-induced
in vitro cell proliferation and in vivo breast tumor growth.
Methods
Animals and tumors
Experiments were carried out using female BALB/c mice
raised at the Instituto de Biología y Medicina Experimental
(IBYME), Buenos Aires, Argentina. Animal experiments
were performed as described previously [33] in accord-
ance with the highest standards of animal care, as outlined
in the US National Institutes of Health Guide for the Care
and Use of Laboratory Animals [34]. The experiments
were approved by the IBYME Animals Research Commit-
tee [5]. The C4HD tumor line displays high levels of es-
trogen receptor (ER) and PR. This tumor line does not
express glucocorticoid or androgen receptors. Progestins
exert a sustained proliferative response in vitro and in vivo
in the C4HD tumor model [35].
Reagents
Medroxyprogesterone acetate (MPA), RU486, (Dulbecco’s)
Modified Eagle’s Medium: Ham F12 1:1 ((D)MEM) and
progesterone were purchased from Sigma Aldrich (Saint
Luis, MO, USA). The transfection reagents Fugene HD and
XtremeGENE HP (Roche Biochemicals, Indianapolis, IN,
USA) were used according to the manufacturer’s instruc-
tions. Cycloheximide was from Sigma-Aldrich (St Louis,
MO, USA) and was used at 1 μM final concentration. Borte-
zomib (VELCADE®) was from Millennium Pharmaceuticals,
Inc (Cambridge, MA, USA) and was used at 100 nM final
concentration; actinomycin D was from Sigma-Aldrich (St
Louis, MO, USA) and was used at a final concentration of
5 μg/ml; myristoylated cAMP-dependent protein kinase
inhibitor (PKI) was from Enzo Life Sciences (Exeter, UK)
and was used at 1 μM final concentration.
Antibodies
The following antibodies were used: anti-GATA3 (HG3-
31, sc-268), anti-cyclin A (C-19, sc-596), anti-cyclin
E (HE12, sc-247), anti-ER (MC-20, sc-542) and anti-PR
(H-190, sc-7208), from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); anti-pSer308-GATA3 (ab61052), anti-
Histone H3 (tri-methyl K27) (ab6002) and anti-Histone
H3 (acetyl K9) (ab4441) from Abcam (Cambridge, MA,
USA); anti-PR (Ab7), anti-actin (clone ACTN05) and anti-
cyclin D1 (RB 9041-P1) from Neomarkers (Freemont,
CA, USA); anti-GAPDH (D16H11), anti-phospho-PKASubstrate (RRXS*/T*)(100G7E) and anti-PKA C-α
(4782) from Cell Signaling (Beverly, MA, USA); anti-
EZH2 (#39933) from Active Motif (Carlsbad, CA,
USA); anti-acetyl-Histone H4 (#06-866) from Millipore
(Temecula, CA, USA); and anti-β-tubulin from Sigma.
Cell culture, treatments and proliferation assays
The human breast cancer cell line T47D was obtained from
the American Type Culture Collection (ATCC) (Manassas,
VA, USA) and T47D-Y cells were a generous gift from Dr.
Horwitz (University of Colorado Health Sciences Center,
Denver, CO, USA). Both cell lines were maintained in (D)
MEM supplemented with 10% fetal calf serum (FCS). Pro-
liferation assays and treatments were performed in (D)
MEM for the T47D cell line. The human breast cancer cell
line BT474 was purchased from the ATCC and maintained
in Roswell Park Memorial Institute (RPMI) 10% FCS. Pri-
mary cultures of epithelial cells from C4HD tumors were
performed as previously described [5]. C4HD cells were
starved and treated in (D)MEM supplemented with 0.1% of
FCS previously depleted of steroids by treatment with ac-
tive charcoal (chFCS). For proliferation assays, 1 x 104 cells
were plated in 96-well plates and allowed to attach over-
night. Cells were starved in (D)MEM for T47D cells or in
(D)MEM 0.1% chFCS for C4HD cells or (D)MEM 1%
chFCS for BT474 cells. Treatments were performed in (D)
MEM or (D)MEM 0.1% chFCS, respectively, with 10 nM
MPA or control vehicle (1:1000 ethanol) for 24 hours. Cell
proliferation was evaluated as the incorporation of 1 μCi
[3H]-thymidine during the last 18 hours of incubation
(New England Nuclear, DuPont, Boston, MA, USA;
specific activity 20 Ci/mmol) as previously described [36].
Assays were performed in octuplicate.
Western blots
Lysates were prepared from cells subjected to the differ-
ent treatments described in each experiment and 50 μg
of proteins were resolved by SDS-page as previously de-
scribed [33]. Membranes were immunoblotted with the
antibodies described in each experiment.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed
as previously described [6]. Primers used for q-PCR are
listed in Table S1 (see Additional file 1).
RNA preparation and real-time RT-PCR
Total RNA was isolated from T47D or C4HD cells
treated as indicated by using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s proto-
col. One microgram of RNA was reverse transcribed using
Superscript III reverse transcriptase (RT) (Invitrogen)
according to the manufacturer’s instructions. Primer
sequences are detailed in Table S1 (see Additional file 1).
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naturing at 95°C and annealing and extension at 60°C for
one minute. The fold change of mRNA expression was
calculated by normalizing the absolute GATA3 mRNA
amounts to GAPDH mRNA levels used as an internal
control.
DNAse sensitivity assay
Cells were harvested in lysis buffer (10 mM Tris-Cl,
pH 7.5; 10 mM NaCl; 3 mM MgCl2; 0.05% NP40) and in-
cubated on ice for 10 minutes. Nuclei were isolated by cen-
trifugation at 2,000 rpm for five minutes at 4°C. The pellet
was washed with digestion buffer (40 mM Tris-Cl pH 7.5;
10 mM MgCl2; 1 mM CaCl2) and centrifuged at
2,000 rpm for five minutes at 4°C. Pellets were resuspended
in 200 μl and each treatment was divided in two tubes (cut
and uncut as input control). Samples were incubated or
not with DNAse I (QR1) (Promega Madison, WI, USA) for
five minutes at 37°C. The reaction was stopped by adding
50 μg of proteinase K and incubating at 65°C for two hours.
DNA was isolated by phenol extraction and ethanol pre-
cipitation. Sensitivity was measured by performing q-PCR
of 100 ng of DNA and calculated as 2^(Ctcut – Ctuncut).
In vivo tumor growth
C4HD cells were transiently transfected with the vec-
tors detailed in the results section. After transfection,
1 x 106 cells were inoculated subcutaneously (s.c.) into
BALB/c mice treated with a 40-mg MPA depot in the
flank opposite to cell inoculum. Tumor volume was
calculated as previously described. The area under the
curve for each sample of each experimental group was
plotted and one-way analysis of variance (ANOVA)
plus Bonferroni post-test were applied to assess statis-
tical significance of differences in tumor growth be-
tween groups.
Plasmids
The pEGFP-N1 empty vector was obtained from BD
Biosciences-Clontech (Palo Alto, CA, USA). The expres-
sion vector encoding GATA3 as a fusion protein with
GFP within the pEGFP-C1 backbone was a generous gift
from Dr. Nakayama (Department of Immunology, Graduate
School of Medicine, Chiba University, Japan). Site directed
mutagenesis was performed on the pEGFP-C1-GATA3 to
produce the replacement of serine 308 for alanine, using the
primers detailed in Table S1 (see Additional file 1). Success-
ful mutation of the sequence was verified by DNA sequen-
cing at the Instituto Nacional de Tecnología Agropecuaria
(INTA) (Buenos Aires, Argentina). The plasmids en-
coding human wild-type PR-B [37] and wild-type PR-A
[38] were kindly provided by Dr. Horwitz and Dr.
Edwards (Baylor College of Medicine, Houston, TX,
USA), respectively.siRNA transfections
siRNAs targeting mouse PR were synthesized by SAB Bio-
sciences (Valencia, CA, USA) and siRNAs targeting hu-
man PR were synthesized by Dharmacon (Lafayette, CO,
USA). A siRNA which does not target any known mam-
malian gene was used as a negative control. The transfec-
tion of siRNA duplexes was performed for two days using
DharmaFECT (Dharmacon) transfection reagent accord-
ing to the manufacturer’s instructions. All siRNA se-
quences are stated in Table S2 (see Additional file 1).
In vitro GATA3 phosphorylation
To study the capacity of endogenous protein kinase (PKA)
to phosphorylate GATA3, T47D cells were treated with
MPA for eight hours, pretreated with PKI for 30 minutes
prior to MPA treatment or kept untreated. Cells were lysed
and PKAs were immunoprecipitated from 1.5 mg of pro-
tein extracts from each cell treatment with an anti-PKA
antibody. GATA3 was immunoprecipitated from 0.5 mg of
protein from T47D cells growing in (D)MEM. Immuno-
precipitated GATA3 was subjected to an in vitro phosphor-
ylation assay with PKAs immunoprecipitated from cells
subjected to each of the treatments described above and as
described in [39]. Samples were analyzed by SDS-PAGE.
Flow cytometry
T47D cells treated with MPA for the indicated times
were harvested with trypsin and fixed in PBS 1% para-
formaldehyde. To determine GATA3 serine phosphoryl-
ation, cells were permeabilized with permeabilization
buffer (PB) (PBS 10% FCS 0.5% saponine) and labeled
with anti-pSer308-GATA3 (1 μg of anti-pSer308-GATA3
antibody per 1 x 106 cells) followed by incubation with anti-
rabbit IgG-Alexa 488. Background staining was evaluated in
cells incubated with an isotype control immunoglobulin G
(IgG) followed by anti-rabbit IgG Alexa 488-conjugated anti-
body. Cells were washed twice with PB, followed by
RNA digestion (RNAse A 50 U/ml) and propidium iod-
ide (20 μg/ml) staining for 30 minutes at room temperature
in the dark. Cell cycle analysis by propidium iodide content
and determination of phospho-GATA3 expression by Alexa
488 fluorescence, were measured using a Canto II flow
cytometer (Becton–Dickinson, La Jolla, CA, USA). The
acquired data were analyzed by FlowJo v5.7.2 software.
Delta mean fluorescence intensity (MFI) values were
obtained by subtracting the MFI of the cells incubated
with control isotype antibody from the MFI of cells in-
cubated with anti-pSer308-GATA3 antibody.
Immunohistochemistry
Immunohistochemistry was performed as previously de-
scribed [40]. Briefly, antigen retrieval was performed in
10 mM sodium citrate buffer pH 6 for 20 minutes at 96°C
to 98°C. Slides were incubated with the primary antibodies
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quently incubated with the polydetector horseradish perox-
idase (HRP) system (Bio SB, Santa Barbara, CA, USA) and
developed in 3-3′-diaminobenzidine tetrahydrochloride.
Immunofluorescence and confocal microscopy
Cells grown in glass coverslips were fixed and perme-
abilized with ice-cold methanol and were then blocked in
PBS 1% bovine serum albumin (BSA). pSer308-GATA3
was localized using the anti-pSer308-GATA3 antibody de-
scribed previously, followed by incubation with anti-rabbit
IgG-Alexa 488 (Molecular Probes, Eugene, OR, USA).
Negative controls were carried out using PBS instead of
primary antibodies. Nuclei were detected by propidium
iodide staining (5 μg/ml). Cells were analyzed using a
Nikon Eclipse E800 confocal laser microscopy system.MPA (18 h)
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Figure 1 PR activation promotes GATA3 downregulation. A) T47D, BT4
(10 nM) for 30 minutes and then coincubated with MPA (10 nM) for the in
expression was measured by western blot (WB). GATA3 bands underwent d
setting the value of untreated cells as 1.0. B) T47D, BT474 or C4HD cells we
PR). Cells were starved for 24 hours and treated with MPA for the indicated
measured by WB. Bands were quantified as described in panel A. C) T47D
(T47D-YA) or PR-B (T47D-YB) isoforms were treated with MPA for 18 hours. B
acetate; PR, progesterone receptor.Results
Progesterone receptor activation promotes
downregulation of GATA3 protein expression
In the present work we used primary cultures of C4HD
epithelial cells from a model of mammary carcinogenesis
induced by MPA in female BALB/c mice [33] and the
PR-positive human breast cancer cell lines T47D and
BT474 [41]. Our first aim was to evaluate whether GATA3
was regulated by PR activation. We found that MPA treat-
ment caused GATA3 downregulation in T47D, BT474
and C4HD cells (Figure 1A). This effect was prevented by
preincubation with the antiprogestin RU486 in all cell
lines tested (Figure 1A) showing the requirement of the
activation of the classical PR for GATA3 downregulation.
T47D cells treated with increasing concentrations of pro-
gesterone, the endogenous PR ligand, displayed similar- -+ +
- +- +
-+ -+
C4HD
YB
.4
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74 or C4HD cells were pretreated or not with the antiprogestin RU486
dicated time. Total protein lysates were prepared and GATA3
ensitometry and values were normalized to GAPDH protein bands
re transfected with control siRNA or with siRNA targeting PR (siRNA
time, total protein lysates were prepared and GATA3 expression was
cells, PR-null T47D-Y cells or T47D-Y cells transfected with either PR-A
ands were quantified as described in panel A. MPA, medroxyprogesterone
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(see Additional file 1: Figure S1). To further demonstrate
the requirement of PR for progestin-mediated GATA3
downregulation, we silenced PR expression using siRNAs
and then performed MPA treatment. In line with the previ-
ous results, PR knockdown prevented GATA3 downregula-
tion by MPA in T47D, BT474 and C4HD cells (Figure 1B).
Accordingly, in the PR-null T47D-Y cells, which derive
from the T47D cell line, MPA failed to regulate GATA3 ex-
pression (Figure 1C). Reconstitution of either isoform B
(PR-B) or isoform A (PR-A) of the PR restored GATA3
regulation by MPA treatment (Figure 1C) indicating that
both isoforms are capable of mediating the MPA effect
on GATA3 expression. These results demonstrate a PR-
mediated decrease of GATA3 expression in breast cancer
cells upon progestin treatment.
Progestins induce transcriptional repression of GATA3 gene
by co-recruitment of progesterone receptor and EZH2
We next explored the mechanism of GATA3 down-
regulation at the transcriptional level. For this pur-
pose, we performed an in silico search [42] for PREs
within 5 kb upstream of the transcriptional start site
(TSS) of GATA3 and found a putative PRE located at
position −1,504 bp to −1,498 bp relative to the TSS
(see Additional file 1: Figure S2). By performing chro-
matin immunoprecipitation (ChIP) assays we found
that PR was significantly recruited to the potential
PRE site in the presence of MPA both in T47D (Figure 2A)
and in BT474 cells (see Additional file 1: Figure S3).
We also found a concomitant increase in H3K27me3
(Figure 2A and Additional file 1: Figure S3), a histone
modification associated with transcriptional repres-
sion [22,23]. Consistently, we observed a decrease in the
acetylation of lysine 9 of histone H3 (H3K9ac) and in the
total acetylation of histone H4 (H4ac) (Figure 2A). Since
H3K27me3 is catalyzed by the histone methyltransferase
EZH2, we tested progestin regulation of EZH2 binding to
the putative PRE site located in GATA3 promoter. Indeed,
EZH2 was significantly recruited to this site in MPA-
treated T47D cells (Figure 2B). To study the requirement
of PR binding to DNA for EZH2 recruitment, we used the
T47D-Y-C587A cell line, which stably expresses a PR har-
boring a substitution of the cysteine 587 for alanine that
renders the receptor unable to bind to DNA or to tether
to other transcription factors bound to DNA [43]. Proges-
tin treatment of T47D-Y-C587A failed to induce EZH2
recruitment to the putative PRE (Figure 2B), indicating
the requirement of PR binding to this site in order to
enable EZH2 recruitment upstream of the GATA3 gene. In
order to further support progestin-induced simultaneous
PR and EZH2 binding to DNA, we performed sequential
ChIP experiments and found that progestin-treated cells
display a significantly increased co-recruitment of PR andEZH2 to the potential PRE as compared to control cells
(Figure 2C). Our results on PR and EZH2 nuclear inter-
action were reinforced by coimmunoprecipitation experi-
ments, showing an increase in PR and EZH2 interaction in
MPA-treated cells (Figure 2D). Since H3K27me3 is associ-
ated with transcriptional repression by chromatin compac-
tion, we next assessed chromatin accessibility at the PRE
by performing DNAse I sensitivity assays using an intra-
genic region of GATA3 as sensitivity control. We found
that MPA treatment decreases DNAse I sensitivity, consist-
ent with a less accessible and repressive chromatin envir-
onment both at the potential PRE and at the TSS regions
(Figure 2E and Additional file 1: Figure S4). In line with
these results, a decrease in GATA3 mRNA levels is ob-
served upon MPA treatment, while RU486 pretreatment
prevented this regulation in both T47D and C4HD cells
(Figure 2F; Additional file 1: Figure S5). GATA3 mRNA
was not downregulated in progestin-treated T47D-Y-
C587A cells (Figure 2F, right panel), which is in accordance
with the lack of EZH2 recruitment observed in Figure 2B.
Taken together, these results demonstrate a PR-mediated
GATA3 transcriptional repression through co-recruitment
of PR and EZH2 to a putative PRE site at the proximal
region of GATA3 promoter, with the concomitant in-
crease of H3K27me3 and decrease of chromatin acces-
sibility, as depicted in Figure 2G.
Progestin exerts GATA3 post-translational regulation
through the 26S proteasome
We found that despite MPA inability to mediate GATA3
transcriptional repression in T47D-Y-C587A cells (Figure 2F)
total GATA3 protein levels were still downregulated by
MPA in this cell line (Figure 3A). This result indicates the
existence of an additional level of regulation of GATA3
expression.
Since it has been reported that GATA3 mRNA stabil-
ity is regulated by RNA binding proteins [44], we first
studied the capacity of MPA to regulate the stability of
GATA3 mRNA. For this purpose we used the transcrip-
tion inhibitor actinomycin D (ActD) and measured the
stability of GATA3 mRNA with or without the addition
of MPA. No significant changes were detected in ActD-
treated cells upon progestin treatment (Figure 3B),
ruling out MPA regulation of GATA3 mRNA stability.
Next, we analyzed GATA3 protein stability using the
translation inhibitor cycloheximide (CHX). Inhibition of
translation with CHX allowed us to measure the stability
of the remaining GATA3 protein relative to initial GATA3
levels. In accordance with previous reports [45], translation
impairment by CHX promoted GATA3 protein decay within
six hours. We found that MPA treatment increased GATA3
turnover (Figure 3C; lane 2 versus lane 4, the densitometric
analysis is shown in the right panel). Since previous studies
have shown GATA3 26S proteasome-mediated degradation
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Figure 2 Transcriptional repression of GATA3 gene by co-recruitment of PR and EZH2. A) Protein recruitment to the GATA3 promoter was
analyzed by ChIP in cells treated as indicated. Immunoprecipitated DNA was amplified by q-PCR using primers flanking the potential PRE located
at position −1,504 bp. Each sample was normalized to the input. Data are expressed as n-fold chromatin enrichment over isotype control. B) T47D
or T47D-Y-C587A cells were treated and ChIP was performed as described in A. C) Chromatins from T47D cells treated or not with MPA were first
immunoprecipitated with PR antibody and then re-immunoprecipitated using EZH2 antibody. The inverse immunoprecipitation order is also shown.
q-PCR analysis of immunoprecipitated DNA was performed as detailed in A. D) Nuclear extracts from T47D cells treated as indicated were
immunoprecipitated (IP) with PR antibody and analyzed by WB with EZH2 antibody . As control of specificity, lysates were immunoprecipitated
with an isotype control. Input cell lysates were blotted in parallel. E) A DNAse sensitivity assay was performed as described in the Methods section,
using the indicated primers detailed in Additional file 1, Table S1. F) T47D or T47D-Y-C587A cells were treated as indicated and GATA3 mRNA
expression levels were determined by RT-qPCR. The fold change of mRNA expression levels upon MPA treatment for the indicated times
was calculated by normalizing the absolute levels of GATA3 mRNA to GAPDH levels, which were used as an internal control, and setting the
value of untreated cells as 1.0. For A, B, C and F, (*P <0.05, **P <0.01 and ***P <0.001, one-way ANOVA). G) Schematic representation of the
mechanism proposed for progestin-induced GATA3 transcriptional repression. ANOVA, analysis of variance; ChIP, chromatin immunoprecipitation;
EZH2, enhancer of zeste homolog 2; MPA, medroxyprogesterone acetate; PR, progesterone receptor; PRE, progesterone response element;
WB, Western blot.
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26S proteasome could be involved in MPA-mediated
GATA3 degradation in breast cancer cells. In order to
address whether GATA3 stability was regulated in a
26S proteasome-dependent manner, we treated cells
with CHX in combination with the 26S proteasome
pharmacological inhibitor bortezomib (Btz). Impairment
of the 26S proteasome function resulted in prevention of
GATA3 protein degradation in the presence of progestin
(Figure 3C; lanes 4 and 5 versus lanes 6 and 7). This result
demonstrates that the 26S proteasome activity is required
for the decrease of GATA3 protein levels by MPA. Previ-
ous studies have shown that PR transcriptional activity
depends on the 26S proteasome function [47]. There-
fore, we speculated that PR-mediated GATA3 repres-
sion could be prevented both at the transcriptional and
post-translational levels by inhibiting the 26S proteasome
activity. Indeed, incubation with Btz resulted in prevention
of GATA3 downregulation upon MPA treatment both at
the mRNA (Figure 3D) and protein levels in T47D and
C4HD cells (Figure 3E and Additional file 1: Figure S6).
These results demonstrate, on the one hand, that GATA3
protein levels are regulated by progestin in a post-
translational manner and, on the other, that inhibition
of the 26S proteasome activity prevents MPA-mediated
GATA3 downregulation at both transcriptional and post-
translational levels.
GATA3 phosphorylation at serine 308 regulates protein
stability
We next addressed whether MPA induces GATA3 phos-
phorylation at serine 308 (pSer308-GATA3), which is lo-
cated within a cAMP-dependent PKA consensus site and
has been shown to be a PKA target in vitro [48]. Confocal
microscopy experiments revealed an increase in phosphory-
lated PKA substrates in T47D cells treated with MPA and
that incubation with the myristoylated PKA inhibitor
(PKI) prevented this effect (see Additional file 1: Figure
S7). An increase in pSer308-GATA3 positive cells uponprogestin treatment was demonstrated by incubation with
an anti-pSer308-GATA3 antibody followed by incubation
with an Alexa 488-conjugated secondary antibody
(Figure 4A). Specificity of the pSer308-GATA3 antibody
was verified by colocalization with total GATA3 and loss
of signal by GATA3 knockdown (see Additional file 1:
Figure S8). MPA and PKI coincubation prevented
MPA-induced GATA3 phosphorylation, as demonstrated
by the decrease in pSer308-GATA3 positive cells (Figure 4A
right panel), showing the requirement of PKA activation
for GATA3 phosphorylation at serine 308 by MPA. To dir-
ectly assess whether PKA could induce phosphorylation of
pSer308-GATA3, immunoprecipitated GATA3 was sub-
jected to a cold in vitro phosphorylation assay as described
in the Methods section. MPA-activated PKA induced
pSer308-GATA3, which was blocked when cells were pre-
treated with PKI (Figure 4B).
On the other hand, PR downregulation by the 26S
proteasome is required for its transcriptional hyperactiv-
ity [49]. To demonstrate that inhibition of the 26S prote-
asome blocked GATA3 degradation due to the effect of
the proteasome per se on GATA3 and not due to
impairment of MPA-induced GATA3 phosphorylation,
we evaluated the effect of Btz on GATA3 phosphoryl-
ation. Confocal microscopy assays showed that pSer308-
GATA3 is induced in the presence of Btz indicating that
the 26S proteasome blockade does not affect the MPA-
induced increase of pSer308-GATA3 (see Additional
file 1: Figure S9).
Notably, cells positive for pSer308-GATA3 were under-
going mitosis, as evidenced by chromatin staining with
propidium iodide (Figure 4C). This observation was con-
firmed by flow cytometry analysis, showing increased
pSer308-GATA3 levels in MPA-treated cells in the S
and G2 phase of the cell cycle compared to cells in G1
(Figure 4C, right panel). MPA-induced pSer308-GATA3
was also observed as a function of DNA content (see
Additional file 1: Figure S10). We next addressed the
relevance of GATA3 phosphorylation at serine 308 for
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Figure 3 Post-translational regulation of GATA3 through the 26S proteasome. A) T47D-Y-C587A cells were treated with MPA for 18 hours,
protein cell lysates were prepared and immunoblotted for the indicated proteins. Signal intensities of GATA3 bands in the WBs were analyzed by
densitometry, values were normalized to GAPDH protein bands setting the value of untreated cells as 1.0. B) T47D cells were treated or not with
MPA and/or actinomycin D (5 μg/μl) for the indicated times. The fold change of mRNA expression levels upon MPA treatment for the indicated
times was calculated by normalizing the absolute levels of GATA3 mRNA to GAPDH levels, which were used as an internal control, and setting
the value of untreated cells as 1.0. Not significant (NS), one-way ANOVA. C) T47D cells were treated or not with cycloheximide (CHX) at 1 μM final
concentration and/or with MPA or bortezomib (Btz) at 100 nM final concentration as indicated, protein cell lysates were prepared and GATA3
expression was measured by WB. Signal intensities of GATA3 bands in the WBs were analyzed as indicated in A. D) T47D cells were pretreated or
not with Btz for 30 minutes and then treated or not with MPA as indicated, and GATA3 mRNA expression was measured by RT-qPCR as described for
B (***P <0.001, one-way ANOVA). E) T47D cells were treated or not with MPA and/or Btz as indicated, protein cell lysates were prepared and
GATA3 expression was measured by WB. Signal intensities of GATA3 bands in the WBs were analyzed as indicated in A. ANOVA, analysis of
variance; MPA, medroxyprogesterone acetate; WB, Western blot.
Izzo et al. Breast Cancer Research  (2014) 16:491 Page 9 of 16GATA3 protein stability. For this purpose, we treated
T47D cells with the PKA inhibitor H89 and measured
GATA3 protein turnover by treatment with CHX in
the presence or absence of MPA. Densitometric ana-
lysis showed that PKA inhibition restored GATA3 pro-
tein stability to levels similar to those of cells treated
with CHX alone (Figure 4D; the densitometric analysis
is shown in the right panel). To further support the
importance of GATA3 phosphorylation at serine 308
for protein stability, we generated a serine-to-alaninesubstitution in position 308 (GFP-GATA3-S308A), a
non-phosphorylable amino acid, in a vector encoding a
GFP-fused wild type protein (GFP-GATA3-WT). Here,
we show by WB analysis that cells transfected with
GFP-GATA3-S308A and treated with CHX showed in-
creased stability of the GFP-GATA3-S308A protein
compared to its wild type counterpart, even in the
presence of the progestin (Figure 4E; the densitometric
analysis is shown in the right panel). Furthermore,
transfection experiments revealed that although MPA
Figure 4 (See legend on next page.)
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Figure 4 GATA3 phosphorylation regulates protein stability. A) T47D cells were treated or not with MPA and the PKA inhibitor PKI (1 μM)
for eight hours. Nuclei were stained with propidium iodide and confocal microscopy analysis was performed. Scale bar = 10 μm. Right panel:
Quantification of pSer308-GATA3 positive cells for the treatments performed in A. Total pSer308-GATA3 intensity relative to cell number was
determined for a minimum of 150 cells per treatment (N = 6) (**P <0.01, ***P <0.001, one-way ANOVA). B) PKA induces pSer308-GATA3
in vitro. T47D cells treated as indicated were lysed and PKAs were immunoprecipitated from protein extracts from each cell treatment.
GATA3 was immunoprecipitated from T47D cells growing in (D)MEM. Immunoprecipitated GATA3 was subjected to a cold in vitro phoshorylation
assay as described in the Methods section. C) Confocal microscopy images of pSer308-GATA3 of cells in different stages of the cell cycle as deter-
mined by propidium iodide staining. Scale bar = 10 μm. The bar plot on the right panel represents a flow cytometry analysis of pSer308-
GATA3 mean fluorescence intensity (MFI) of different stages of the cell cycle as determined by DNA content (***P <0.001, Student’s t-test).
D) T47D cells were treated with CHX and/or with MPA or H89 (1 μM) for the indicated times. GATA3 bands of WBs underwent densitometry
and values were normalized to GAPDH protein bands setting the value of untreated cells as 1.0. The results are graphically represented in a line
plot. E) Cells were transfected with the indicated vectors for 48 hours, starved for 24 hours and treated as indicated. Densitometric analysis of WB was
performed as in D. F) Cells were transfected as in E and densitometric analysis was performed as in D. G) Proposed model for GATA3 post-translational
regulation by progestin. ANOVA, analysis of variance; CHX, cycloheximide; MPA, medroxyprogesterone acetate; PKA, protein kinase; WB, Western blot.
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ous GATA3 and GFP-GATA3-WT proteins, it was un-
able to downregulate the GFP-GATA3-S308A mutant
protein to a similar extent (Figure 4F). Since a consti-
tutive promoter drives exogenous GATA3 expression,
this experiment validates, on the one hand, the MPA-
mediated post-translational downregulation of GATA3
and, on the other hand, demonstrates the requirement
of phosphorylation at serine 308 for increased GATA3
protein turnover. The presented results link GATA3
phosphorylation at serine 308 with protein stability and
demonstrate the requirement of GATA3 phosphorylation
to achieve MPA-induced GATA3 protein degradation.
A schematic representation of the mechanism described
is shown (Figure 4G).
GATA3 downregulation is required for progestin-induced
cell proliferation and increased cyclin A2 levels
Progestin stimulation of in vitro and in vivo breast can-
cer is well acknowledged [33,50]. Given the present re-
sults showing that GATA3 is phosphorylated in serine
308 during cell cycle progression (Figure 4C) and that
impairment of such phosphorylation prevents GATA3
downregulation by MPA (Figure 4F), we next investi-
gated the association between GATA3 downregulation
and progestin-induced in vitro proliferation and in vivo
tumor growth. In order to assess the effect of GATA3
overexpression in cell proliferation, we transfected T47D
cells with either GFP-GATA3-WT or GFP-GATA3-S308A
and used [3H]-thymidine incorporation as a measure of
cell proliferation. Transfection of GFP-GATA3-WT vector
impaired MPA-induced proliferation in T47D, C4HD and
BT474 cells (Figure 5A and Additional file 1: Figure S11,
respectively) showing that increased GATA3 levels pre-
vent MPA-induced proliferation. We observed that trans-
fection of the mutant form GFP-GATA3-S308A resulted
in a significantly enhanced repression of proliferation
compared to GFP-GATA3-WT (Figure 5A). These results
are consistent with the previously observed increasedstability of the GFP-GATA3-S308A mutant protein in the
presence of progestin (Figure 4F) and show the require-
ment of GATA3 downregulation for MPA-induced cell
proliferation.
Analysis of a publicly available microarray dataset
showed that cyclin A2 was the only member of the cyc-
lin family that was significantly downregulated upon
GATA3 overexpression in MDA-MB-231 breast cancer
cells [32] (see Additional file 1: Figure S12). We found
an increase in cyclin A2 expression levels at 12 hours
and 18 hours of progestin treatment (Figure 5B). More-
over, transfection of GFP-GATA-WT or GFP-GATA3-
S308A prevented cyclin A2 upregulation in MPA-treated
T47D cells (Figure 5C). In line with previous reports
[32], MDA-MB-231 cells also displayed decreased cyclin
A2 levels when transfected with the GFP-GATA3-WT
vector (see Additional file 1: Figure S13). We then ad-
dressed the effect of GATA3 overexpression in in vivo
tumor growth. For this purpose, 106 C4HD cells previ-
ously transfected with the GFP control vector, GFP-
GATA3-WT, or GFP-GATA3-S308A expression vectors
were inoculated subcutaneously into BALB/c mice treated
or not with MPA, and tumor growth was measured.
C4HD tumor growth displayed a progestin-dependent
behavior as previously reported [36], since absence of
the MPA pellet resulted in lack of tumor growth in
GFP-transfected cells, and inoculation of the MPA pellet
induced tumor growth (Figure 6A). GFP-GATA3-WT
overexpression significantly reduced progestin-dependent
tumor growth, and this effect was significantly enhanced
in GFP-GATA3-S308A tumors (Figure 6A). Decreased
levels of cyclin A2 were detected in GFP-GATA3-S308A
tumors compared to GFP or GATA3-WT tumors, while
levels of cyclin D1 and cyclin E were similar across treat-
ments (Figure 6B). The expression levels of cyclin A2 in
the tumor samples studied by immunohistochemistry
were in line with the results obtained by WB, with de-
creased cyclin A2 levels in GFP-GATA3-S308A tumors
(Figure 6C). Taken together, these results account for a
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Figure 5 GATA3 downregulation is required for progestin-induced cell proliferation and increased cyclin A2 levels. A) T47D cells were
transfected with the indicated vectors for 48 hours and cell proliferation was measured as described in the Methods section. Not significant (NS),
(***P <0.001, one-way ANOVA). B) Cells were treated with MPA for the indicated times, protein lysates were prepared and immunoblotted for the
indicated proteins. The densitometry values were obtained by normalizing cyclin A to GAPDH protein bands and setting the value of untreated
cells as 1.0. C) Cells were transfected with the indicated vectors for 48 hours, starved for 24 hours and treated as indicated. Protein lysates were
prepared and immunoblotted for the indicated proteins. Bands were quantified as described for panel B. ANOVA, analysis of variance; MPA,
medroxyprogesterone acetate.
Izzo et al. Breast Cancer Research  (2014) 16:491 Page 12 of 16role of GATA3 as a negative regulator of MPA-induced
cell proliferation through prevention of cyclin A2 up-
regulation, and demonstrate the requirement of GATA3
downregulation for progestin-driven breast cancer
growth.Discussion
Progesterone receptor-mediated transcriptional
repression
Transcriptional repression is a key step in the regulation
of cellular processes. In the present work, we have iden-
tified a putative PRE site located in position -1,504 bp
relative to the TSS of GATA3. We also demonstrated
that PR is involved in the transcriptional repression of
this gene. We underscored the relevance of GATA3 re-
pression in PR-induced cell proliferation, and described
the capability of PR to co-recruit EZH2, the catalytic
subunit of PRC2 to the potential PRE site in GATA3
proximal promoter. This recruitment resulted in increased
H3K27me3, chromatin compaction and transcriptional re-
pression. We have also shown that progestin treatment
promotes a decrease in H3K9ac and H4ac, which suggests
the involvement of additional mechanisms in the process
of GATA3 repression, such as recruitment of histone dea-
cetylases. Notably, we here show that activation of PR by
progestins induces the interaction between PR and EZH2,
suggesting that this mechanism could be potentially in-
volved in the repression of other PR target genes. Further
investigation may provide valuable tools for the design ofinhibitors of the assembly between PR and EZH2 which
may hold therapeutic value.
The role of PcG in cell differentiation through repres-
sion of target genes is well acknowledged. The regulation
of EZH2 by progesterone in the mammary gland [25]
suggests that its activity may be linked to the action of
hormone receptors. Therefore, EZH2 may be directed to
a subset of target genes by hormonal cues. Regulation of
the master transcription factor GATA3 through PR and
EZH2 co-recruitment is in accordance with the reported
role of PcG in cell fate transitions through regulation of
genes involved in cell differentiation [24], as is the case
of GATA3. It would be of interest to determine which sites
are bound by both PR and EZH2 in normal mammary
gland and in breast cancer cells by the use of genome-wide
approaches, potentially allowing the identification of target
genes repressed by PR in an EZH2-dependent manner. If
the transcriptional repression described here for the
GATA3 locus proves to be a general mechanism for
PR-mediated target gene repression, it could set the ra-
tionale for the use of EZH2 inhibitors in order to prevent
PR-driven breast cancer progression, by blocking the re-
pression of tumor suppressor genes and promoting a
more differentiated status of breast cancer cells.Cyclin A2 regulation by GATA3
Cell cycle transitions are controlled by cyclin-dependent
kinases (CDKs), whose activity depends on the interaction
with specific cyclins which have distinctive expression
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Figure 6 GATA3 downregulation is required for progestin-induced in vivo tumor growth. A) C4HD cells (106) from each experimental
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shown. Scale bar = 20 μm. ANOVA, analysis of variance; MPA, medroxyprogesterone acetate.
Izzo et al. Breast Cancer Research  (2014) 16:491 Page 13 of 16patterns during progression of the cell cycle. Particularly,
cyclin D1 expression peaks during the G1 phase of the cell
cycle and interacts with Cdk2, Cdk4 and Cdk6 promoting
the progression of the G1 phase of the cell cycle. Further-
more, cyclin A2 is expressed in proliferative somatic cellsand its expression peaks during the S and G2 phases of
the cell cycle, since it mediates the onset of DNA replica-
tion and, therefore, the transition from G1 to S phase of
the cell cycle [28]. The results presented here suggest
that GATA3 blockade of MPA-induced proliferation
Izzo et al. Breast Cancer Research  (2014) 16:491 Page 14 of 16may involve direct cyclin A2 transcriptional repression.
The close participation of GATA3 in mammary luminal cell
fate favors the possibility of GATA3 regulating cell
cycle progression. Indeed, several reports demonstrate
GATA3 transcriptional regulation of factors which have
pivotal functions in cell cycle control, for example, p18
(ink4c) [51,52] and cyclin D1 [53,54] where GATA3 binds
to its responsive element in the respective promoters.
Notably, the human cyclin A2 proximal promoter con-
tains three GATA3 binding sites, two of them located in
tandem at position -171 bp and another one mapped at
-2,496 bp [42]. Further research is required to evaluate
whether GATA3 alone, or as part of an enhanceosome, is
recruited to these binding sites to repress MPA-induced
cyclin A2 transcription.
On the one hand, GATA3 has been reported to be re-
quired for cyclin D1 expression [54] and on the other
hand, we show here that GATA3 downregulation is needed
for progestin-induced cyclin A2 levels. Notably, MPA
phosphorylation of GATA3 at Ser 308 is induced at S/G2
suggesting that this event may precede cyclin A2 increase
by progestin. These results indicate that GATA3 may
coordinate the expression of these two cyclins. Our
present demonstration of GATA3 regulation at both
the transcriptional and post-translational levels may
indicate the importance of the temporal coordination
of its expression in order to synchronize the expression
patterns of both cyclin D1 and cyclin A2. The two in-
dependent mechanisms described here for GATA3
downregulation may provide fine tuning to GATA3 ex-
pression. Further insight into the role of GATA3 in co-
ordinating cell cycle progression may contribute to clarify
its role in breast cancer.
Relevance of GATA3 phosphorylation as a potential
prognosis marker
Several studies demonstrated that GATA3 expression
holds independent prognostic value of a favorable out-
come in breast cancer patients [15-17,19]. In the present
work, we show the role of GATA3 phosphorylation at serine
308 for PR-induced GATA3 protein turnover. We have also
shown that the capability of the non-phosphorylable mutant
GFP-GATA3-S308A to prevent MPA-induced breast cancer
cell proliferation is enhanced compared to its wild-type
counterpart, as demonstrated in the in vivo assay in the
C4HD preclinical model. Given the presented results estab-
lishing a link between GATA3 phosphorylation and in-
creased protein turnover, we propose that determining
pSer308-GATA3 levels in breast cancer patients could be
predictive of GATA3 loss. The detection of pSer308-GATA3
could allow stratification of GATA3 positive tumors and
identification of those predicted to lose GATA3 expression,
which would be expected to bear a worse prognosis.
The latter group of patients could benefit from antiprogestintreatment to prevent GATA3 degradation and hence pre-
vent progestin-induced tumor growth.Conclusions
The results of this study demonstrate that progestins
downregulate GATA3 transcript through PR binding up-
stream of the GATA3 gene, EZH2 recruitment and chro-
matin compaction. We have also shown that PR activation
leads to PKA-mediated GATA3 phosphorylation at serine
308, which results in 26S proteasome-mediated GATA3
protein degradation. Finally, we demonstrated that
GATA3 downregulation is essential for cyclin A2 up-
regulation and progestin-driven breast cancer growth.Additional file
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figures and tables cited in this article.Abbreviations
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